Dr. Rizvi is the Professor of Medicine in the Department of Medicine and the Director of Thoracic Oncology Phase I Immunotherapeutics for the Division of Hematology and Oncology at Columbia University Medical Center in New York, NY. He also holds the Price Chair in Clinical Translational Research.
Dr. Rizvi is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer.
Dr. Rizvi’s research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up to Cancer – Cancer Research Institute Immunology funding.
In his research, he also is studying why certain cancers do not respond to immune checkpoint inhibitors, so we can find better ways to harness the immune system to attack cancer cells. He oversees phase 1 immunotherapy research in solid tumors at Columbia University Medical Center and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.
Dr. Rizvi has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a shareholder/co-founder of Gritstone Oncology.
- Professor of Medicine
Department of Medicine
Director, Thoracic Oncology and Phase I Immunotherapeutics
Division of Hematology and Oncology
Columbia University Medical Center
New York, NY